2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2066

Anti-Ds-DNA Antibodies Regulate Atherothrombosis in Systemic Lupus Erythematosus through the Induction of Netosis, the Prothrombotic and Proinflammatory Activities of Monocytes and the Endothelial Activation
Abstract Number: 1128

Anti-Fractalkine Monoclonal Antibody Inhibits Cartilage Destruction and Bone Erosion in Collagen-Induced Arthritis Model
Abstract Number: 2325

ANTI-Hmgcr Antibodies Demonstrate High Diagnostic VALUE in the Diagnosis of Immune Mediated Necrotizing Myopathy Following Statin Exposure
Abstract Number: 3039

Anti-IL-17A, but Not Anti-TNF, Can Halt Pathological New Bone Formation in Experimental Spondyloarthritis
Abstract Number: 2954

Anti-IL6-R Tocilizumab in Refractory Uveitis Associated with BehçEt’s Disease. Multicenter Study of 11 Patients
Abstract Number: 2260

Anti-Inflammatory Role of Lubricin/Proteoglycan 4 (PRG4) in Monosodium Urate (MSU)-Crystal Induced Arthritis.
Abstract Number: 247

ANTI-Interleukin 1 Therapy in FMF Amyloidosis: A Single Center Experience
Abstract Number: 2314

Anti-Mi2 Dermatomyositis Revisited: Pure DM Phenotype with Muscle Fiber Necrosis and High Risk of Malignancy
Abstract Number: 126

Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in African-American Patients: Disease Associations and Clinical Outcomes in an Urban Cohort
Abstract Number: 572

Anti-Periodontal Bacteria Antibody Titers Are Inversely Correlated with ACPA in RA-Free Individuals with Periodontal Disease Compared to Community Controls
Abstract Number: 2898

Anti-Reflux Medications in Diffuse Cutaneous Systemic Sclerosis: Is Empiric Use of Proton Pump Inhibitors Supported?
Abstract Number: 752

Anti-Ro Positivity Is a Predictor of Responsiveness to Topical Steroids or Hydroxychloroquine in Patients with Discoid but Not Subacute Cutaneous Lupus
Abstract Number: 1383

ANTI-RO/SSA and/or ANTI-La/SSB Antibodies: Association with Mild LUPUS Manifestations in 645 Childhood-Onset Systemic LUPUS Erythematosus
Abstract Number: 2841

Anti-Ro52/TRIM21 Antibodies Are Associated with QT Interval Prolongation in Patients with Systemic Lupus Erythematosus
Abstract Number: 2312

Anti-TIF1-Gamma Antibodies Are Not Associated with Other Paraneoplastic Rheumatic Syndromes Than Dermatomyositis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].